News for Healthier Living
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced updated long-term follow-up data from the pivotal study of PAPZIMEOS(tm) (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP).
June 1, 2026
June 3 2026June 2 2026June 1 2026 - Nursing Home Staffing Declined in States That Protected Facilities From COVID-19 Malpractice Lawsuits
- Mount Sinai Researchers Uncover a Substantial Genetic Component to Postpartum Psychosis, Advancing Understanding of Severe Maternal Mental Illness
- Blood Test Shows Promise for Detecting Testicular Cancer When Standard Markers Miss
- UChicago renewed to host NRG Oncology Statistics and Data Management Center for National Cancer Institute
- Clinical Trial Shows Novel Prostate Cancer Treatment Can Reduce Risk of Disease Progression by Half
- Deep Brain Stimulation Remodels Brain Wiring and Alters Functional Changes to Brain-Wide Networks, Landmark Depression Study Reveals
- 7 Trends Reshaping Pediatric Hip Dysplasia Care
- Lab Research Suggests Magnetic Particle Imaging May Help Researchers Find More Effective Ways to Deliver Cell Therapies
- Split Personalities: Researchers Who Bridge Disciplines
- From Fundamental Biology to Treatments for Disease, Stem Cells are Engines of Discovery
- Joan A. Steitz: The 'Queen of RNA' and Her Scientific Feats
- Many Adults with a Normal BMI May Still Have Obesity-Related Health Risks
- Body Mass Index Found to Drastically Underestimate Obesity Levels in the United States
- Your Surprise Medical Bill May Be Gone — But Your Premiums Could Still Spike
- Short-Term Fasting Could Boost Chemo Response in Ovarian Cancer, Study Suggests
- New Analysis Confirms Benefits of Childhood Flu Vaccines
- Hormone Therapy Use for Menopause Declines Despite Proven Benefits, Study Finds
- Powering Every Step: $2M to Develop Knee Exoskeletons for Arthritis Relief, Mobility
- JMIR Report: Digital Platforms and Policy Shifts Reshape GLP-1 Affordability
- Researchers Create First-of-Its-Kind Index of Evolving Policy Landscape Around Health Care AI
- Perfectionism Among College Students Reaches Record High, Fueling Anxiety
- Workout Habits May Protect Against Inherited Heart Problems
- New Survey Results Explore the Complexity of Marijuana Use and Sleep
- Childhood Lying Is Normal and Rarely Signals Behavioral Concerns, Study Says
- Weed Linked To Higher Testosterone Levels In Young Men
- After Her Bout of Amnesia, A $59,000 Billing Dispute Wouldn't Go Away
- Most People Over 50 Have LGBTQ+ Friends or Family, but LGBTQ+ People Over 50 Face More Aging-Related Challenges, Poll Finds
- ASCO: Targeted Therapy Combo Nearly Doubles Time Without Disease Progression for Patients with Advanced Colorectal Cancer
- Virtual Eyes in the Operating Room: AI Detects Surgical Safety Landmark Across Hospitals
- Post-Discharge Antibiotics May Offer Limited Benefit After Pediatric Appendicitis
- Teamwork, Technology Streamline Feeding Tube Placement
- Tomorrow at ASCO 2026: Roswell Park Researchers Spotlight New Insights in Breast Cancer, Myeloma Care and AI
- Study: New Drug Could Dramatically Increase Pancreatic Cancer Survival
- Investigational Targeted Therapy Doubles Survival in Metastatic Pancreatic Cancer
- Targeted Therapy Reduces Risk of Lung Cancer Recurrence by 83% in Rare Genetic Subtype
- Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
- June 2026 Issue of Neurosurgical Focus: "Craniopharyngioma: Contemporary Management"
May 31 2026May 30 2026May 29 2026May 28 2026May 27 2026May 26 2026May 25 2026May 22 2026May 21 2026
|
|
|
|
|